On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex-Reference-Cited by-同舟云学术

On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex

Published:2021-03-19 Issue:4 Volume:59 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Köser Claudio U.¹^ORCID,Georghiou Sophia B.²,Schön Thomas³⁴⁵,Salfinger Max⁶

Affiliation:

1. Department of Genetics, University of Cambridge, Cambridge, United Kingdom

2. FIND, Geneva, Switzerland

3. Department of Infectious Diseases, Kalmar County Hospital, Linköping University, Kalmar, Sweden

4. Unit of Infection and Inflammation, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

5. Department of Infectious Diseases, Linköping University Hospital, Linköping, Sweden

6. University of South Florida College of Public Health and Morsani College of Medicine, Tampa, Florida, USA

Abstract

In a recent report of a systematic review of critical concentrations (CCs), the World Health Organization (WHO) lowered the rifampin (RIF) CC for antimicrobial susceptibility testing (AST) of the Mycobacterium tuberculosis complex using Middlebrook 7H10 medium and the Bactec mycobacterial growth indicator tube (MGIT) 960 system from 1 to 0.5 μg/ml. The previous RIF CC for 7H10 had been in use for over half a century.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.02328-20

Reference45 articles.

1. Rifampin in the Treatment of Drug-ResistantMycobacterium tuberculosisInfections

2. The Diagnosis and Therapy of Tuberculosis During the Past 100 Years

3. World Health Organization. 2020. Global tuberculosis report 2020. World Health Organization Geneva Switzerland. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf.

4. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis

5. Targeted next-generation sequencing: a Swiss army knife for mycobacterial diagnostics?;Mohamed S;Eur Respir J

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection of multidrug-resistance in Mycobacterium tuberculosis by phenotype- and molecular-based assays;Annals of Clinical Microbiology and Antimicrobials;2024-08-28

2. First detection of a Mycobacterium tuberculosis XDR clinical isolate harbouring an RpoB I491F mutation in a Ukrainian patient treated in Germany, October 2023;Eurosurveillance;2024-07-11

3. Discordant results between Xpert MTB/RIF assay and Bactec MGIT 960 culture system regarding the detection of rifampin-resistant Mycobacterium tuberculosis isolates in Wenzhou, China;Microbiology Spectrum;2024-06-04

4. Rifampicin has no role in treatment ofMycobacterium aviumcomplex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint;European Respiratory Journal;2024-05

5. Refined understanding of the impact of the Mycobacterium tuberculosis complex diversity on the intrinsic susceptibility to pretomanid;Microbiology Spectrum;2024-03-05